ArticleEuropean journal of nuclear medicine and molecular imaging2016
Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- The global research of magnetic resonance imaging in Alzheimer's disease: a bibliometric analysis from 2004 to 2023.Frontiers in neurology · 2024Pooled it
- A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimers disease patients relative to healthy controls and mild cognitive impairment patients.Neurosciences (Riyadh, Saudi Arabia) · 2017Pooled it
- Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020Trial
- Cerebellar cortical amyloid deposition biasesEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- Assessment of early-phase [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
- Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers.European journal of clinical investigation · 2026Review
- Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review.Brain sciences · 2025Review
- Evaluation of early-phaseJournal of Alzheimer's disease : JAD · 2025Article
- Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2025Article
- Early-phaseEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Toxicity Concerns Associated with the Radiopharmaceuticals for the Diagnosis of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Article
- Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer's disease preclinical phase evaluated by dual-phaseScientific reports · 2024Article
- PET image denoising based on denoising diffusion probabilistic model.European journal of nuclear medicine and molecular imaging · 2024Article
- Feasibility evaluation of middle-phaseQuantitative imaging in medicine and surgery · 2023Article
- Generation of ConventionalMedicina (Kaunas, Lithuania) · 2023Article
- Assessment of perfusion deficit with early phases of [European journal of nuclear medicine and molecular imaging · 2023Article
- Alzheimer's Disease Prediction Using Attention Mechanism with Dual-PhaseNuclear medicine and molecular imaging · 2023Article
- Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[(18)F]FDG is a commonly used neuronal injury biomarker for early and differential diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose consumption. Early uptake of the Aβ tracer [(11)C]PiB on PET images is mainly determined by cerebral blood flow and shows a high correlation with [(18)F]FDG uptake. Uptake data for (18)F-labelled Aβ PET tracers are, however, scarce. We investigated the value of early PET images using the novel Aβ tracer [(18)F]FBB in the diagnosis of Alzhimers disease (AD).
methodsThis retrospective analysis included 22 patients with MCI or dementia who underwent dual time-point PET imaging with either [(11)C]PiB (11 patients) or [(18)F]FBB (11 patients) in routine clinical practice. Images were acquired 1 - 9 min after administration of both tracers and 40 - 70 min and 90 - 110 min after administration of [(11)C]PiB and [(18)F]FBB, respectively. The patients also underwent [(18)F]FDG brain PET imaging. PET data were analysed visually and semiquantitatively. Associations between early Aβ tracer uptake and dementia as well as brain atrophy were investigated.
resultsRegional visual scores of early Aβ tracer and [(18)F]FDG PET images were significantly correlated (Spearman's ρ = 0.780, P < 0.001). Global brain visual analysis revealed identical results between early Aβ tracer and [(18)F]FDG PET images. In a VOI-based analysis, the early Aβ tracer data correlated significantly with the [(18)F]FDG data (r = 0.779, P < 0.001), but there were no differences between [(18)F]FBB and [(11)C]PiB. Cortical SUVRs in regions typically affected in AD on early Aβ tracer and [(18)F]FDG PET images were correlated with MMSE scores (ρ = 0.458, P = 0.032, and ρ = 0.456, P = 0.033, respectively). A voxel-wise group-based search for areas with relatively higher tracer uptake on early Aβ tracer PET images compared with [(18)F]FDG PET images revealed a small cluster in the midbrain/pons; no significant clusters were found for the opposite comparison.
conclusionEarly [(18)F]FBB and [(11)C]PiB PET brain images are similar to [(18)F]FDG PET images in AD patients, and these tracers could potentially be used as biomarkers in place of [(18)F]FDG. Thus, Aβ tracer PET imaging has the potential to provide biomarker information on AD pathology and neuronal injury. The potential of this approach for supporting the diagnosis of AD needs to be confirmed in prospective studies in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.